chenodeoxycholic acid has been researched along with t0901317 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Abraham, DJ; Lin, HR | 1 |
| Carotti, A; Colliva, C; De Franco, F; Filipponi, P; Franco, P; Gadaleta, RM; Gioiello, A; Macchiarulo, A; Moschetta, A; Mostarda, S; Passeri, D; Pellicciari, R; Roda, A | 1 |
| Carotti, A; Ciaccioli, G; Gioiello, A; Passeri, D; Pellicciari, R; Pittol, JMR; van Mil, SWC | 1 |
| Bhatnagar, S; Dridi, S; Hillgartner, FB; Talukdar, S | 1 |
| He, JG; Lu, XH; Lv, GP; Si, SY; Zhang, H; Zhao, BH; Zheng, ZH | 1 |
| Cheng, J; Hu, H; Qu, X; Yan, W; Zhang, T; Zhou, X | 1 |
| Blankestijn, M; Capkova, N; Dvorak, A; Jonker, JW; van de Peppel, IP; Verkade, HJ; Vitek, L | 1 |
7 other study(ies) available for chenodeoxycholic acid and t0901317
| Article | Year |
|---|---|
Identification of a lead pharmacophore for the development of potent nuclear receptor modulators as anticancer and X syndrome disease therapeutic agents.
Topics: Antineoplastic Agents; Cell Line; Chemistry, Pharmaceutical; Chenodeoxycholic Acid; DNA-Binding Proteins; Drug Design; Genes, Reporter; Humans; Metabolic Syndrome; Models, Chemical; Models, Molecular; Neoplasms; Protein Binding; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Transcriptional Activation; Transfection; Two-Hybrid System Techniques | 2006 |
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
Topics: | 2016 |
Dissecting the allosteric FXR modulation: a chemical biology approach using guggulsterone as a chemical tool.
Topics: | 2019 |
Chenodeoxycholic acid suppresses the activation of acetyl-coenzyme A carboxylase-alpha gene transcription by the liver X receptor agonist T0-901317.
Topics: Acetyl-CoA Carboxylase; Animals; Binding Sites; Chenodeoxycholic Acid; Chick Embryo; DNA-Binding Proteins; Hydrocarbons, Fluorinated; Liver X Receptors; Orphan Nuclear Receptors; p38 Mitogen-Activated Protein Kinases; Receptors, Cytoplasmic and Nuclear; Sterol Regulatory Element Binding Protein 1; Sulfonamides; Transcriptional Activation | 2007 |
Impacts of different promoters on the mammalian one-hybrid assay for detecting nuclear receptor agonists.
Topics: Animals; Bezafibrate; Cells, Cultured; Chenodeoxycholic Acid; Drug Discovery; Genetic Vectors; HeLa Cells; High-Throughput Screening Assays; Humans; Hydrocarbons, Fluorinated; Ligands; Mice; NIH 3T3 Cells; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Promoter Regions, Genetic; Pyrimidines; Rosiglitazone; Sensitivity and Specificity; Structure-Activity Relationship; Sulfonamides; Thiazolidinediones; Two-Hybrid System Techniques | 2010 |
Liver X receptor agonist methyl-3β-hydroxy-5α,6α-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride.
Topics: Animals; Apolipoproteins E; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cells, Cultured; Chenodeoxycholic Acid; Dose-Response Relationship, Drug; Gene Expression Regulation; Humans; Hydrocarbons, Fluorinated; Liver X Receptors; Macrophages; Male; Mice; Mice, Knockout; Orphan Nuclear Receptors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Triglycerides | 2010 |
Induction of fecal cholesterol excretion is not effective for the treatment of hyperbilirubinemia in Gunn rats.
Topics: Animals; Bile; Bile Acids and Salts; Bilirubin; Chenodeoxycholic Acid; Cholesterol; Crigler-Najjar Syndrome; Dietary Fats; Ezetimibe; Feces; Haptoglobins; Hydrocarbons, Fluorinated; Hyperbilirubinemia; Intestines; Lipids; Liver X Receptors; Male; PPAR delta; Random Allocation; Rats; Rats, Gunn; Receptors, Cytoplasmic and Nuclear; Sulfonamides | 2021 |